Liu Hsin-Yi, Tam Ka-Wai, Loh El-Wui, Liu Wan-Chi, Kuo Hsien-Cheng, Li Chun-Cheng, Cherng Yih-Giun, Chen Jui-Tai, Tai Ying-Hsuan
Department of Anesthesiology, Shuang Ho Hospital, Taipei Medical University, No. 291, Zhongzheng Rd., Zhonghe District, New Taipei City, 23561, Taiwan.
Department of Anesthesiology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
Perioper Med (Lond). 2021 Dec 6;10(1):41. doi: 10.1186/s13741-021-00212-5.
Procedural sedation reduces patients' discomfort and anxiety, facilitating performance of the examination and intervention. However, it may also cause adverse events, including airway obstruction and hypoxia. We conducted this systematic review and meta-analysis to evaluate the efficacy of high-flow nasal oxygenation (HFNO) compared with that of standard oxygen therapy in adult patients undergoing procedural sedation.
We identified randomized controlled trials published before November 2020 based on PubMed, Embase, and Cochrane Library databases and ClinicalTrials.gov registry. Intraprocedural desaturation [peripheral oxygen saturation (SpO) < 90%] was evaluated as the primary outcome. The secondary outcomes were the lowest SpO, need for airway intervention, oxygen therapy-related complications, and patient, operator, and anesthetist's satisfaction.
Six trials with a total of 2633 patients were reviewed. Patients using HFNO compared with standard oxygen therapy had a significantly lower risk of intraprocedural desaturation [risk ratio 0.18, 95% confidence interval (CI) 0.04-0.87]. The lowest intraprocedural SpO in HFNO group was significantly higher than that in standard oxygen therapy group (mean difference 4.19%, 95% CI 1.74-6.65).
Compared with standard oxygen therapy, HFNO may reduce the risk of desaturation and increase the lowest SpO in adult patients undergoing sedation for medical procedures.
程序性镇静可减轻患者的不适与焦虑,便于检查及干预操作的进行。然而,其也可能引发不良事件,包括气道梗阻和低氧血症。我们开展了此项系统评价和荟萃分析,以评估在接受程序性镇静的成年患者中,高流量鼻导管给氧(HFNO)与标准氧疗相比的疗效。
我们依据PubMed、Embase、Cochrane图书馆数据库及ClinicalTrials.gov注册库,检索了2020年11月之前发表的随机对照试验。术中低氧血症(外周血氧饱和度(SpO)<90%)被评估为主要结局。次要结局包括最低SpO、气道干预需求、氧疗相关并发症以及患者、操作者和麻醉医生的满意度。
共纳入6项试验,总计2633例患者。与标准氧疗相比,使用HFNO的患者术中出现低氧血症的风险显著更低(风险比0.18,95%置信区间(CI)0.04 - 0.87)。HFNO组术中最低SpO显著高于标准氧疗组(平均差值4.19%,95% CI 1.74 - 6.65)。
与标准氧疗相比,HFNO可能降低接受医疗操作镇静的成年患者出现低氧血症的风险,并提高最低SpO。